Neoleukin Therapeutics, Inc. NLTX
Set alert
3.49 0.00 0.00%
At close · Dec 18
3.42 Day range 3.59
52-week range unavailable
- Open
- 3.45
- Prev close
- 3.49
- Mkt cap
- 8.20M
- Vol
- 109.09K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.42
- High
- 3.59
- Forward P/E
- -20.53
- Beta
- 1.10
- Short ratio
- 1.70
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 14, 2023
- 50-d avg
- 13.83
- 200-d avg
- 14.98
- 1y target
- 1.50
2Y chart
Events in this range
- Aug 9, 2022Earnings: —; estimate -1.5; surprise —%
- Nov 14, 2022Earnings: —; estimate -1.6; surprise —%
- Mar 21, 2023Earnings: —; estimate 0; surprise —%
- May 8, 2023Earnings: —; estimate -0.9; surprise —%
- Aug 10, 2023Earnings: —; estimate -0.75; surprise —%
- Sep 25, 2023Split: 1 for 5
- Nov 14, 2023Earnings: —; estimate -0.8; surprise —%
Signals (89)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Dec 18, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 18, 2023 | 2 years ago |
| MACD: Sell Signal | Dec 13, 2023 | 2 years ago |
| SMA: Bearish | Dec 11, 2023 | 2 years ago |
| SMA: Bullish | Dec 7, 2023 | 2 years ago |
| SMA: Bearish | Nov 29, 2023 | 2 years ago |
| SMA: Bullish | Nov 28, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 8, 2023 | 2 years ago |
| MACD: Sell Signal | Nov 7, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 6, 2023 | 2 years ago |
| SMA: Bearish | Oct 16, 2023 | 3 years ago |
| SMA: Bearish | Oct 13, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 12, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 28, 2023 | 3 years ago |
| SMA: Bullish | Sep 25, 2023 | 3 years ago |
| SMA: Bullish | Sep 25, 2023 | 3 years ago |
| SMA: Bearish | Sep 22, 2023 | 3 years ago |
| SMA: Bearish | Sep 21, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 14, 2023 | 3 years ago |
| SMA: Bullish | Sep 13, 2023 | 3 years ago |
| SMA: Bearish | Sep 11, 2023 | 3 years ago |
| RSI: Overbought | Sep 7, 2023 | 3 years ago |
| SMA: Bullish | Aug 31, 2023 | 3 years ago |
| SMA: Bearish | Aug 23, 2023 | 3 years ago |
| SMA: Bullish | Aug 22, 2023 | 3 years ago |
| SMA: Bearish | Aug 21, 2023 | 3 years ago |
| SMA: Bullish | Aug 18, 2023 | 3 years ago |
| SMA: Bullish | Aug 15, 2023 | 3 years ago |
| MACD: Buy Signal | Aug 15, 2023 | 3 years ago |
| RSI: Oversold | Aug 10, 2023 | 3 years ago |
| SMA: Bearish | Aug 7, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 19, 2023 | 3 years ago |
| SMA: Bearish | Jul 18, 2023 | 3 years ago |
| RSI: Overbought | Jul 17, 2023 | 3 years ago |
| SMA: Bullish | Jul 11, 2023 | 3 years ago |
| SMA: Bearish | Jul 10, 2023 | 3 years ago |
| SMA: Bullish | Jul 6, 2023 | 3 years ago |
| MACD: Buy Signal | Jun 26, 2023 | 3 years ago |
| RSI: Oversold | Jun 15, 2023 | 3 years ago |
| SMA: Bearish | Jun 5, 2023 | 3 years ago |
| SMA: Bullish | Jun 1, 2023 | 3 years ago |
| SMA: Bearish | May 31, 2023 | 3 years ago |
| MACD: Sell Signal | May 5, 2023 | 3 years ago |
| RSI: Overbought | Apr 28, 2023 | 3 years ago |
| RSI: Overbought | Apr 20, 2023 | 3 years ago |
| SMA: Bullish | Apr 10, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 29, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 28, 2023 | 3 years ago |
| SMA: Bullish | Mar 9, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 9, 2023 | 3 years ago |
| RSI: Overbought | Mar 9, 2023 | 3 years ago |
| SMA: Bearish | Feb 24, 2023 | 3 years ago |
| SMA: Bullish | Feb 23, 2023 | 3 years ago |
| SMA: Bearish | Feb 16, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 9, 2023 | 3 years ago |
| MACD: Buy Signal | Feb 7, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 2, 2023 | 3 years ago |
| SMA: Bullish | Dec 29, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 25, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 15, 2022 | 3 years ago |
| RSI: Oversold | Nov 15, 2022 | 3 years ago |
| RSI: Oversold | Nov 8, 2022 | 3 years ago |
| RSI: Oversold | Oct 20, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 14, 2022 | 4 years ago |
| RSI: Oversold | Sep 21, 2022 | 4 years ago |
| SMA: Bearish | Sep 12, 2022 | 4 years ago |
| SMA: Bullish | Sep 9, 2022 | 4 years ago |
| SMA: Bearish | Aug 29, 2022 | 4 years ago |
| MACD: Sell Signal | Aug 29, 2022 | 4 years ago |
| SMA: Bullish | Aug 12, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 12, 2022 | 4 years ago |
| SMA: Bearish | Aug 9, 2022 | 4 years ago |
| SMA: Bullish | Aug 4, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 27, 2022 | 4 years ago |
| RSI: Overbought | Jul 20, 2022 | 4 years ago |
| SMA: Bullish | Jul 15, 2022 | 4 years ago |
| SMA: Bearish | Jul 11, 2022 | 4 years ago |
| SMA: Bullish | Jul 7, 2022 | 4 years ago |
| RSI: Oversold | May 13, 2022 | 4 years ago |
| RSI: Oversold | May 11, 2022 | 4 years ago |
| MACD: Buy Signal | May 2, 2022 | 4 years ago |
| RSI: Oversold | Apr 29, 2022 | 4 years ago |
| MACD: Sell Signal | Apr 13, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 17, 2022 | 4 years ago |
| MACD: Sell Signal | Mar 14, 2022 | 4 years ago |
| RSI: Oversold | Mar 14, 2022 | 4 years ago |
| RSI: Oversold | Feb 23, 2022 | 4 years ago |
| RSI: Oversold | Feb 17, 2022 | 4 years ago |
| RSI: Oversold | Jan 20, 2022 | 4 years ago |
Key statistics
- Market cap
- 8.20M
- Enterprise value
- -35.02M
- Trailing P/E
- 0.00
- Forward P/E
- -20.53
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.10
- EPS (TTM)
- -12.28
- Beta
- 1.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -19.73M
- Total cash
- 78.51M
- Total debt
- 10.69M
- Return on equity
- -37.88%
- Shares outstanding
- 2.35M
- Short % of float
- 0.28%
- 50-day average
- 13.83
- 200-day average
- 14.98
Analyst view
Consensus: hold
Hold
Price target (mean) 1.50
Next earnings
Nov 14, 2023
Expected Nov 14, 2023. Consensus EPS estimate 0.00.
Financials — quick view
NLTX Revenue — quarterly 0
NLTX Net income — quarterly -2.08M
NLTX EPS — quarterly -0.04
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2023 | Sep 1, 2023 | -0.80 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | -0.75 | — | — | — |
| May 8, 2023 | Mar 1, 2023 | -0.90 | — | — | — |
| Mar 21, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -1.60 | — | — | — |
| Aug 9, 2022 | Jun 1, 2022 | -1.50 | — | — | — |
About Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- neoleukin.com
News
- Neoleukin Therapeutics (NASDAQ:NLTX) & Zymeworks (NASDAQ:ZYME) Critical Contrast
- Reviewing Intellipharmaceutics International (OTCMKTS:IPCIF) & Neoleukin Therapeutics (NASDAQ:NLTX)
- Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
- Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
- Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc
- NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX
- Shareholder Alert: Ademi LLP investigates whether Neoleukin Therapeutics, Inc. has obtained a Fair Price in its Private Placement and its transaction with Neurogene
- NLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to Shareholders
- Neurogene and Neoleukin Announce Definitive Merger Agreement
- Neoleukin Therapeutics: Strategic Review Play
Your note
Sign in to keep a note on NLTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 16, 2023 | 0 |
| DRACHMAN JONATHAN G | Chief Executive Officer | Stock Gift | Oct 25, 2021 | 2,398,690 |
| HO ROBERT | Chief Financial Officer | Sale | Mar 16, 2021 | 21,503 |
| LEVITT DANIEL J | Director | Sale | May 13, 2018 | 0 |
| MACKENZIE LLOYD | Chief Operating Officer | Sale | Mar 14, 2018 | 0 |
| MAIN DAVID J | Chief Executive Officer | Sale | Jun 4, 2017 | 71,530 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Brothers Advisors, LLC | 1.74% | 764,348 | 3.17M | Jun 29, 2023 |
| Lynx1 Capital Management Lp | 1.41% | 618,911 | 2.57M | Jun 29, 2023 |
| Redmile Group, LLC | 1.32% | 582,446 | 2.42M | Jun 29, 2023 |
| Bank of America Corporation | 0.53% | 232,004 | 962.82K | Jun 29, 2023 |
| Vanguard Group Inc | 0.46% | 202,162 | 838.97K | Jun 29, 2023 |
| Renaissance Technologies, LLC | 0.43% | 187,445 | 777.90K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.22% | 95,768 | 397.44K | Jun 29, 2023 |
| Vanguard Total Stock Market Index Fund | 0.22% | 98,708 | 409.64K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.08% | 34,362 | 137.45K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.02% | 7,394 | 29.58K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.02% | 9,650 | 38.60K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 4,506 | 18.02K | May 30, 2023 |